Phospho-SREBF1 (S439) Antibody

What is SREBF1 and why is S439 phosphorylation significant?

SREBF1 (Sterol Regulatory Element Binding Transcription Factor 1) is a key transcription factor that controls genes involved in cholesterol biosynthesis and lipid homeostasis. The phosphorylation at serine 439 (S439) is particularly significant because it occurs specifically during mitosis and plays a crucial role in stabilizing the mature form of SREBF1 during cell division. This phosphorylation creates a phosphoepitope recognized by the mitotic protein monoclonal-2 (MPM-2) antibody. The modification is essential for preserving a critical pool of active transcription factors that support lipid synthesis during cell proliferation, establishing a direct link between cell cycle progression and metabolic regulation .

How does Phospho-SREBF1 (S439) antibody differ from general SREBF1 antibodies?

Phospho-SREBF1 (S439) antibody specifically detects SREBF1 protein only when phosphorylated at the serine 439 position, while general SREBF1 antibodies recognize the protein regardless of its phosphorylation status. This phospho-specific antibody enables researchers to selectively visualize the form of SREBF1 that has undergone this specific post-translational modification, providing valuable insights into temporal regulation during mitosis that would not be possible with general SREBF1 antibodies . The specificity of this antibody makes it an indispensable tool for investigating cell cycle-dependent regulation of SREBF1 function.

What is the precise epitope recognized by Phospho-SREBF1 (S439) antibody?

The Phospho-SREBF1 (S439) antibody specifically recognizes an epitope containing the phosphorylated serine residue at position 439 in the human SREBF1 protein. According to manufacturer specifications, the immunogen used to generate this antibody is a synthesized peptide derived from the region around the phosphorylation site of Ser439, typically within amino acids 405-454 . This carefully designed epitope ensures that the antibody detects endogenous SREBF1 protein only when phosphorylated at S439, providing high specificity for studying this particular post-translational modification.

What validated applications exist for Phospho-SREBF1 (S439) antibody?

Phospho-SREBF1 (S439) antibody has been validated for multiple research applications:

These applications enable comprehensive investigation of phosphorylated SREBF1 (S439) across different experimental contexts, particularly in studies related to cell cycle regulation and lipid metabolism .

How should samples be prepared for optimal detection of phosphorylated SREBF1?

For optimal detection of phosphorylated SREBF1 at S439, sample preparation should carefully preserve the phosphorylation status:

• Use phosphatase inhibitor cocktails in all lysis and extraction buffers to prevent dephosphorylation during sample preparation.

• Since S439 phosphorylation is mitosis-specific, synchronize cells or enrich for mitotic populations (using nocodazole treatment or mitotic shake-off) to enhance detection sensitivity.

• Process samples quickly and maintain cold temperatures throughout preparation to minimize phosphorylation loss.

• For Western blotting, use phosphate-buffered saline (PBS) with phosphatase inhibitors and appropriate detergents for membrane protein extraction.

• For IHC/IF applications, optimize fixation protocols to preserve phosphoepitopes—paraformaldehyde fixation is often preferred over harsher fixatives that may destroy phospho-specific epitopes.

• Consider using positive controls such as TNF-treated Jurkat cell extracts, which have demonstrated strong phospho-SREBF1 (S439) signals in validation studies .

What controls should be included when using Phospho-SREBF1 (S439) antibody?

When designing experiments with Phospho-SREBF1 (S439) antibody, several critical controls should be included:

• Positive control: Mitotic cell extracts, where S439 phosphorylation is known to occur, or TNF-treated Jurkat cells (20ng/ml for 30 minutes) as documented in antibody validation data .

• Negative control: G1-phase synchronized cells where S439 phosphorylation should be minimal or absent.

• Phosphatase treatment control: Treating duplicate samples with lambda phosphatase to demonstrate signal loss when phosphorylation is removed.

• Blocking peptide control: Competition assay using the phosphorylated peptide immunogen to confirm antibody specificity.

• Secondary antibody-only control: To identify potential non-specific background from the detection system.

These controls provide crucial validation of signal specificity and help distinguish true phospho-SREBF1 detection from experimental artifacts.

How does Cdk1/cyclin B mediate SREBF1 phosphorylation at S439?

The Cdk1/cyclin B complex plays a direct role in phosphorylating SREBF1 at S439 during mitosis. Research has demonstrated that:

• Mature SREBF1 physically interacts with the Cdk1/cyclin B complex specifically in mitotic cells.

• Cdk1 has been demonstrated to phosphorylate S439 both in in vitro kinase assays and in living cells.

• This phosphorylation event is part of a larger regulatory network that coordinates cell division with metabolic processes.

• The phosphorylation by Cdk1/cyclin B provides a molecular mechanism that stabilizes mature SREBF1 during mitosis, preserving a pool of active transcription factors to support lipid synthesis during cell division .

This direct link between a master regulator of mitosis (Cdk1/cyclin B) and a key metabolic transcription factor (SREBF1) represents an important molecular mechanism coordinating cell cycle progression with metabolic demands.

How does S439 phosphorylation affect SREBF1 stability and function?

S439 phosphorylation has significant effects on SREBF1 protein stability and function:

• Stabilization: The mature form of SREBF1 is stabilized in a phosphorylation-dependent manner during mitosis, with S439 being a critical site mediating this effect.

• Degradation protection: Phosphorylation at S439 appears to protect mature SREBF1 from degradation pathways that would otherwise reduce its abundance during mitosis.

• Transcriptional activity preservation: By maintaining SREBF1 protein levels, this phosphorylation ensures continued transcriptional regulation of lipid synthesis genes through the mitotic phase.

• Cell cycle progression support: Research indicates that SREBF1 activity influences cell cycle progression, as siRNA-mediated inactivation of SREBF1 arrests cells in the G1 phase, suggesting a bidirectional relationship between SREBF1 and cell cycle control .

This phosphorylation-mediated stabilization represents an elegant mechanism linking cell cycle kinase activity to metabolic regulation.

What cellular pathways are influenced by SREBF1 S439 phosphorylation?

SREBF1 S439 phosphorylation influences several interconnected cellular pathways:

• Lipid biosynthesis: By stabilizing SREBF1 during mitosis, S439 phosphorylation helps maintain the expression of genes involved in cholesterol and fatty acid synthesis during cell division.

• Cell cycle regulation: The research shows that SREBF1 activity impacts cell cycle progression, with its inactivation causing G1 arrest, suggesting that proper regulation of SREBF1, including through phosphorylation, supports normal cell proliferation .

• Mitotic processes: The specific timing of S439 phosphorylation during mitosis suggests a coordinated regulation between mitotic events and metabolic activities.

• SREBF1 processing pathway: While indirect, the phosphorylation may interact with the canonical SREBF1 processing pathway involving SCAP and site-specific proteases that regulate SREBF1 activation .

These interconnections highlight the role of S439 phosphorylation as a regulatory node connecting cell division with metabolic homeostasis.

How can Phospho-SREBF1 (S439) antibody be used to study cell cycle-dependent metabolism?

Phospho-SREBF1 (S439) antibody enables sophisticated approaches to investigate cell cycle-dependent metabolism:

• Cell cycle profiling: Combining the antibody with DNA content analysis in flow cytometry or immunofluorescence microscopy to correlate S439 phosphorylation with specific cell cycle phases.

• Chromatin immunoprecipitation (ChIP): Using the phospho-specific antibody for ChIP experiments to analyze how S439 phosphorylation affects SREBF1 binding to target gene promoters during different cell cycle phases.

• Kinase inhibition studies: Examining how modulation of Cdk1/cyclin B activity (through chemical inhibitors or genetic approaches) affects SREBF1 phosphorylation, stability, and subsequent metabolic gene expression.

• Metabolic flux analysis: Pairing detection of phosphorylated SREBF1 with measurement of lipid synthesis rates through isotope labeling to directly correlate phosphorylation status with metabolic activity.

• Proteomics approaches: Immunoprecipitating phosphorylated SREBF1 to identify co-regulated proteins or additional modifications that may cooperate with S439 phosphorylation .

These methodologies provide complementary approaches to understanding how SREBF1 phosphorylation integrates cell cycle progression with metabolic regulation.

What experimental designs can elucidate the temporal dynamics of S439 phosphorylation?

To investigate the temporal dynamics of S439 phosphorylation, researchers can implement these experimental designs:

• Synchronized cell population analysis: Use methods like double thymidine block, nocodazole arrest/release, or mitotic shake-off to synchronize cells, followed by time-course analysis with the phospho-specific antibody.

• Single-cell immunofluorescence: Combine Phospho-SREBF1 (S439) staining with established cell cycle markers (such as PCNA for S-phase, phospho-histone H3 for mitosis) to examine phosphorylation patterns in individual cells at different cycle stages.

• Live-cell imaging approaches: While challenging with antibody-based detection, developing fluorescent reporters based on phospho-binding domains could enable real-time visualization of phosphorylation dynamics.

• Quantitative Western blot analysis: Perform densitometry on Western blots from cells at defined cell cycle stages to measure relative levels of phosphorylation throughout the cell cycle progression.

• Phosphorylation/dephosphorylation kinetics: Use specific kinase inhibitors or phosphatase activators to manipulate phosphorylation status, followed by time-course analysis to determine rates of modification and reversal.

These approaches would provide comprehensive data on when S439 phosphorylation occurs, how long it persists, and how it correlates with other cell cycle events.

How can Phospho-SREBF1 (S439) antibody be utilized in cancer research?

Phospho-SREBF1 (S439) antibody offers several valuable applications in cancer research:

• Tumor profiling: Assess phosphorylation levels across different cancer types to identify correlations with proliferation rates, metabolic phenotypes, or patient outcomes.

• Cell cycle dysregulation analysis: Examine whether cancer-associated cell cycle aberrations affect the normal pattern of SREBF1 phosphorylation and subsequent lipid metabolism.

• Therapeutic response studies: Investigate how cancer therapeutics targeting cell cycle (CDK inhibitors) or metabolism affect SREBF1 phosphorylation and downstream metabolic pathways.

• Biomarker development: Evaluate whether Phospho-SREBF1 (S439) levels could serve as biomarkers for mitotic index, proliferation status, or response to particular therapies.

• Combination therapy rationale: Provide molecular evidence for combining metabolism-targeting and cell cycle-targeting therapies based on SREBF1 phosphorylation status.

Since many cancers display both cell cycle dysregulation and metabolic reprogramming, investigating SREBF1 phosphorylation could reveal important connections between these cancer hallmarks and potentially identify new therapeutic vulnerabilities .

What are common technical challenges when using Phospho-SREBF1 (S439) antibody?

Researchers commonly encounter several technical challenges when working with Phospho-SREBF1 (S439) antibody:

• Phosphoepitope preservation: Phosphorylation sites can be rapidly dephosphorylated by endogenous phosphatases during sample preparation, necessitating stringent use of phosphatase inhibitors.

• Cell cycle-dependent signal: Since S439 phosphorylation occurs specifically during mitosis, unsynchronized cell populations typically show weak signals due to the small proportion of mitotic cells (typically <5%).

• Antibody specificity: As with many phospho-specific antibodies, ensuring specificity requires careful validation and appropriate controls.

• Sample handling: Phosphorylation status can be easily compromised by prolonged sample processing at room temperature or inadequate phosphatase inhibition.

• Fixation artifacts in IHC/IF: Inappropriate fixation methods can mask phosphoepitopes or create false-positive signals.

Addressing these challenges requires careful optimization of protocols and implementation of appropriate controls for each experimental system .

How can researchers validate the specificity of phospho-specific detection?

Validating the specificity of phospho-specific detection requires multiple complementary approaches:

• Phosphatase treatment: Treating duplicate samples with lambda phosphatase to demonstrate signal loss when phosphorylation is removed.

• Cell cycle correlation: Since S439 phosphorylation is mitosis-specific, signals should correlate strongly with established mitotic markers like phospho-histone H3.

• Kinase manipulation: Inhibiting Cdk1 (known to phosphorylate S439) should reduce the signal if the antibody is truly phospho-specific.

• Peptide competition: Pre-incubating the antibody with phosphorylated and non-phosphorylated peptides to demonstrate phospho-specificity through selective signal blocking.

• Signal correlation with cell synchronization: Signal intensity should predictably increase in mitotically-enriched populations and decrease in G1-enriched populations.

These validation approaches provide overlapping evidence for antibody specificity and should ideally be used in combination to ensure reliable detection of phosphorylated SREBF1 .

What strategies can overcome weak or inconsistent phospho-SREBF1 (S439) detection?

To improve detection of phosphorylated SREBF1 at S439, researchers can implement these strategies:

• Cell synchronization: Enrich for mitotic cells using nocodazole treatment or mitotic shake-off to increase the proportion of cells with S439 phosphorylation.

• Antibody optimization: Carefully titrate antibody concentration for each application, testing the full recommended dilution range (WB: 1:500-1:2000; IHC: 1:100-1:300; IF: 1:50-1:200) .

• Signal amplification techniques: For Western blotting, use high-sensitivity detection reagents; for IHC/IF, consider tyramide signal amplification or polymer detection systems.

• Extended primary antibody incubation: Overnight incubation at 4°C often improves signal detection compared to shorter incubations.

• Sample enrichment: Consider phosphoprotein enrichment prior to Western blotting to concentrate the target protein.

• Buffer optimization: Test different blocking agents and washing conditions to minimize background while preserving specific signals.

These optimization strategies should be systematically tested and documented to identify the optimal conditions for detecting phosphorylated SREBF1 in each experimental system.